Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSoutheast University, China

About this trial

Although the theoretical model of "cyclic on-off switching of pulmonary blood flow" provides a crucial perspective for understanding VILI, its clinical validation and real-time intervention face significant obstacles. The fundamental reason lies in the lack of pulmonary microcirculation monitoring technology capable of bedside, non-invasive, continuous operation with sufficient spatiotemporal resolution. Nowadays, a novel 3D-EIT can perform real-time and non-invasive assessment of the distribution of pulmonary blood flow. However, if 3D-EIT can help to identify "cyclic on-off switching of pulmonary blood flow" is still unclear.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients with mechanical ventilation

diagnosis of moderate to severe ARDS no more than 72 hours

Disqualifiers

Chronic respiratory diseases that required long-term oxygen therapy, such as pulmonary fibrosis or chronical obstructive pulmonary disease

Contraindications to EIT (e.g., active implantable device, chest malformation, unstable spinal injuries or fractures, and open chest wounds)

Undrained pneumothorax or pneumomediastinum,

Hemodynamic instability

Trial population

Consecutive adult patients admitted to our ICU were screened for inclusion and exclusion criteria

Trial design

Design model

Case-crossover

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

40 Participants
are grouped into 3 trial groups
Group A: phase 1
Group B: phase 2
Group C: phase 3

Trial outcomes

Primary outcomes

1

The percent of "Cyclic On-Off Switching"

"Cyclic On-Off Switching" was assessed by 3D-EIT

Time frame
15min

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: